QMS to add diagnostics R&D through binding BeamOptics MOU
Key highlights
- QMS signed a binding MOU on September 25, 2026 to acquire 100% of BeamOptics.
- BeamOptics brings diagnostic R&D, regulatory processes and in-house manufacturing, with seven patents filed reported by QMS.
- QMS reported Q2 FY27 revenue of Rs 52.5 crore, up 18% year on year, while PAT declined 32% to Rs 2.4 crore.
- Consideration for BeamOptics may be cash, a share swap or both, based on an independent valuation.
powered by IRIS

QMS Medical Allied Services Limited signed a binding memorandum of understanding on September 25, 2026 to acquire 100% of BeamOptics, subject to stated conditions, adding diagnostic research and development, regulatory capabilities and in-house manufacturing to QMS’s sales, marketing and nationwide distribution business.
Know QMS Medical Allied Services inside out
Results, valuation, peers and who's buying, in one view.
What has QMS agreed to acquire from BeamOptics?
QMS has agreed through a binding MOU dated September 25, 2026 to acquire 100% of BeamOptics, which the presentation identifies as a Pune-based diagnostics and analytical deep-tech company. The proposed transaction is intended to add diagnostic technology and value-added healthcare products to QMS’s existing product operations, which provide sales, marketing and distribution.
QMS may pay consideration in cash, through a share swap, or through a combination of the two, with the method based on an independent valuation. The presentation gives no purchase price, valuation, share-swap ratio or completion date. It says finalisation depends on mutual fulfilment of terms and conditions and approval of the composite scheme involving Health Care At Home India Pvt. Ltd. by the National Company Law Tribunal, or NCLT.
The presentation also states that the acquisition is not a related-party transaction and that QMS’s promoter group has no interest in BeamOptics. This separation matters because the MOU’s 100% acquisition structure remains conditional, rather than a completed purchase, and the eventual consideration mechanism has not been selected.
What diagnostic capabilities would BeamOptics add to QMS?
BeamOptics would add research and development, or R&D, compliance and manufacturing functions to QMS’s product business. Its disclosed development work includes RedCheck optical sensing, the QCare universal reader platform and a Fourier-transform infrared, or FTIR, analytical-instrument line. The presentation reports seven patents filed and separately says that two products are commercial and six are in rollout.
The target’s compliance infrastructure includes Central Drugs Standard Control Organisation test licences and quality-agreement management for every stock-keeping unit, or SKU. Its manufacturing facility is described as having assembly, quality-control and line-readiness capabilities. The source also cites MD-5 manufacturing licences, without providing licence numbers, capacity or production volumes.
QMS brings a business-to-business point-of-care diagnostics network serving clinics, laboratories and screening programmes across India. The presentation says its marketing, healthcare communications, digital strategy and e-commerce channels have been built over more than 30 years, while its logistics and channel-partner relationships turn manufactured devices into stocked products for sale.
Got a follow-up? Ask IRIS
How would BeamOptics fit into QMS’s wider restructuring?
BeamOptics would fit within QMS’s product business, which the presentation says will remain in the currently listed entity with no change in current shareholding. The proposed combination is presented as a full-stack product operation, linking R&D and manufacturing with sales, distribution and last-mile customer access.
This plan runs alongside a separate composite scheme approved by QMS and Health Care At Home India Pvt. Ltd. on September 25, 2026. Under that scheme, their patient support programme, or PSP, service businesses would be combined into Saarathi Healthcare, a QMS subsidiary, while the product business would stay with QMS.
The PSP arrangement contemplates an all-share swap under which 1.32 crore shares would be issued to Health Care At Home India Pvt. Ltd. shareholders, with Saarathi Healthcare intended to list separately on the National Stock Exchange, or NSE. The presentation shows QMS promoters holding 1.32 crore shares, or 40.5%, and the public holding 0.62 crore shares, or 19%, after the issuance, alongside a 40.5% holding for the incoming shareholders.
What do QMS’s latest results show before the proposed deal?
QMS reported net revenue from operations of Rs 52.5 crore in Q2 FY27, up 18% from Rs 44.7 crore in Q2 FY26, but earnings before interest, tax, depreciation and amortisation, or EBITDA, declined 6% to Rs 6.5 crore. EBITDA margin fell to 12.4% from 15.5%, while profit after tax, or PAT, declined 32% to Rs 2.4 crore from Rs 3.6 crore.
For H1 FY27, meaning the first half of financial year 2027 as labelled by the source, revenue rose 20% to Rs 109.4 crore from Rs 91.2 crore. EBITDA increased 11% to Rs 14.8 crore from Rs 13.4 crore, but PAT fell 5% to Rs 6.4 crore from Rs 6.7 crore. The EBITDA margin was 13.6%, compared with 14.7% a year earlier.
The source records employee expenses of Rs 23.7 crore in H1 FY27, up from Rs 6.3 crore in H1 FY26, while cost of goods sold declined to Rs 47.8 crore from Rs 51.5 crore. It does not assign these movements to BeamOptics or quantify the proposed acquisition’s future revenue, profit, manufacturing capacity or financial contribution.
Conclusion
The September 25, 2026 binding MOU would shift QMS’s product platform beyond commercial distribution by combining its sales and channel network with BeamOptics’ diagnostic R&D, regulatory processes and manufacturing. The proposed 100% acquisition is distinct from the PSP services restructuring, although the MOU makes NCLT approval of that composite scheme a condition to finalisation.
The next disclosed matters to watch are fulfilment of the MOU’s terms and conditions, NCLT approval of the Health Care At Home India Pvt. Ltd. scheme, and the independent valuation that will determine whether consideration is cash, shares or both. QMS has not disclosed the transaction value, share-swap ratio, closing date or BeamOptics financial contribution.


